Tim Brecklinghaus1. 1. Leibniz Research Centre for Working Environment and Human Factors at the Technical University of Dortmund (IfADo), 44139, Dortmund, Germany.
Recently Pascual and colleagues have contributed a study about the identity of cells that initiate metastasis (Pascual et al., 2017[22]). They identified a cell type in humanoral carcinomas with the following properties: (1) slow-cycling, (2) CD44-bright, (3) low expression of mesenchymal genes, (4) ability to initiate metastasis in mouse models and (5) high expression of the fatty acid receptor CD36. CD36 is a membrane protein on the surface of many mammalian cells that imports fatty acids (Yang et al., 2018[34]; Umbarawan et al., 2018[31]; Son et al., 2018[28]). CD36 has been shown to be critical for supply with fatty acids and for maintenance of energy metabolism under numerous conditions (Wen et al, 2017[33]; Chen et al, 2016[5]; Nakatani et al., 2015[21]; le Foll et al., 2015[15], 2013[14]). In their recent study Pascual et al. report that neutralizing antibodies against CD36 reduce the formation of metastasis in orthotopic mouse models of oral cancer (Pascual et al., 2017[22]). A further finding of this study is that NOD scid gamma mice developed larger lymph node metastases in a CD36 dependent manner, when the mice received a high-fat diet. Moreover, the authors report that CD36 positive cells are metastasis initiating and are characterized by a lipid metabolism signature (Pascual et al., 2017[22]). Based on publicly available data, high expression of CD36 was associated with poor disease-free survival in breast, lung and urinary bladder cancer (Pascual et al., 2017[22]).In the past decade much progress has been made in understanding the principles that control formation of metastases (McGranahan et al, 2017[20]; Lambert et al., 2017[13]; Adawy, 2017[1]; Marchan, 2012[18]; Cadenas, 2012[2]; Mantovani et al., 2017[17]; Zhan et al, 2017[35]). It is generally accepted that the cellular and humoral immune system play an important role in preventing metastasis (Schmidt et al., 2018[25], 2012[24], 2008[23]; Godoy et al., 2014[6]; Heimes et a., 2017[8][9]; Sicking et al., 2014[26]).In many tumor types high expression of proliferation associated genes has been shown to lead to an increased risk of metastasis (Schmidt et al., 2008[23]; Siggelkow et al., 2012[27]; Jabs et al., 2017[11]; Wei et al,, 2017[32]; Knaack, et al, 2018[12]). Moreover, high expression of antioxidative factors (Cadenas et al, 2010[3]), disturbed expression of genes involved in the control of circadian rhythm (Cadenas et al., 2014[4]) and actin binding proteins (Stock et al., 2015[30]) are associated with shorter metastasis-free interval.Different principles have been shown to control breast cancer metastasis that occurs within the first three years after the primary tumor or later (Hellwig et al., 2016[10]; Hammad et al., 2016[7]). Finally, factors involved in glycerophospholipid metabolism have been shown to influence the capacity of tumor cells to migrate, attach to surfaces and to metastasize (Stewart et al., 2012[29]; Lesjak et al., 2014[16]; Marchan et al., 2017[19]).In conclusion, Pascual and colleagues bring forward an interesting concept that metastasis-initiating tumor cells rely on dietary lipids in a CD36 dependent manner. It remains to be shown, whether CD36 is a promising target for anti-cancer therapy.
Authors: Christelle Le Foll; Ambrose A Dunn-Meynell; Barry E Levin Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-12-04 Impact factor: 3.619
Authors: Marcus Schmidt; Birte Hellwig; Seddik Hammad; Amnah Othman; Miriam Lohr; Zonglin Chen; Daniel Boehm; Susanne Gebhard; Ilka Petry; Antje Lebrecht; Cristina Cadenas; Rosemarie Marchan; Joanna D Stewart; Christine Solbach; Lars Holmberg; Karolina Edlund; Hanna Göransson Kultima; Achim Rody; Anders Berglund; Mats Lambe; Anders Isaksson; Johan Botling; Thomas Karn; Volkmar Müller; Aslihan Gerhold-Ay; Christina Cotarelo; Martin Sebastian; Ralf Kronenwett; Hans Bojar; Hans-Anton Lehr; Ugur Sahin; Heinz Koelbl; Mathias Gehrmann; Patrick Micke; Jörg Rahnenführer; Jan G Hengstler Journal: Clin Cancer Res Date: 2012-02-20 Impact factor: 12.531
Authors: Cristina Cadenas; Dennis Franckenstein; Marcus Schmidt; Mathias Gehrmann; Matthias Hermes; Bettina Geppert; Wiebke Schormann; Lindsey J Maccoux; Markus Schug; Anika Schumann; Christian Wilhelm; Evgenia Freis; Katja Ickstadt; Jörg Rahnenführer; Jörg I Baumbach; Albert Sickmann; Jan G Hengstler Journal: Breast Cancer Res Date: 2010-06-28 Impact factor: 6.466
Authors: Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Joanna D Stewart; Rosemarie Marchan; Michaela S Lesjak; Joerg Lambert; Roland Hergenroeder; James K Ellis; Chung-Ho Lau; Hector C Keun; Gerd Schmitz; Juergen Schiller; Mandy Eibisch; Christian Hedberg; Herbert Waldmann; Ekkehart Lausch; Berno Tanner; Jalid Sehouli; Jens Sagemueller; Hagen Staude; Eric Steiner; Jan G Hengstler Journal: Proc Natl Acad Sci U S A Date: 2012-05-08 Impact factor: 11.205
Authors: Michaela S Lesjak; Rosemarie Marchan; Joanna D Stewart; Eugen Rempel; Jörg Rahnenführer; Jan G Hengstler Journal: Cell Adh Migr Date: 2014-10-31 Impact factor: 3.405